If you or someone close to you is managing multiple myeloma that has returned or is not responding to treatment, you may be eligible for a clinical trial evaluating investigational CAR T-cell therapy. CAR T-cell therapy uses your body’s own cells to fight cancer.
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma.
This clinical trial is designed specifically for individuals with multiple myeloma that has returned or has not responded to treatment.
Talk to your doctor about the iMMagine-3 clinical trial to find out if this study is right for you.
*Anitocabtagene autoleucel (anito-cel) is an investigational agent. The safety and efficacy of anito-cel have not been established, and it has not been approved by the US Food and Drug Administration (FDA) or other regulatory authorities.
© 2017-2025 Gilead Sciences, Inc. All rights reserved.
For Kite Medical Information, Clinical Trial Inquiries, Adverse Events, and Product Complaints please contact: (844) 454-KITE (5483), Monday–Friday 5 am–6 pm PT, Kite Medical Information: https://kitemedinfo.com